Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
Go back to Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)| Alexion Pharmaceuticals (NASDAQ: ALXN) | Delayed: 182.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $182.01 | 52 Week High | $193.45 | |||
| Open | $33.31 | 52 Week Low | $110.56 | |||
| Day High | $182.01 | P/E | 143.31 | |||
| Day Low | $182.01 | EPS | $1.27 | |||
| Volume | 71 | |||||
